<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MEDI</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28723796</article-id><article-id pub-id-type="pmc">5521936</article-id><article-id pub-id-type="publisher-id">MD-D-17-02010</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000007582</article-id><article-id pub-id-type="art-access-id">07582</article-id><article-categories><subj-group subj-group-type="heading"><subject>3800</subject></subj-group><subj-group><subject>Research Article</subject><subject>Clinical Trial/Experimental Study</subject></subj-group></article-categories><title-group><article-title>Moist exposed burn ointment for treating pressure ulcers</article-title><subtitle>A multicenter randomized controlled trial</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Wei</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Yubo</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Qi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Yu</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Qinggang</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref rid="cor1" ref-type="corresp"><sup>∗</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Comim.</surname><given-names>Fabio</given-names></name></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Medical Science Institute of Harbin, the First Hospital of Harbin, Harbin Medical University, Harbin</aff><aff id="aff2"><label>b</label>Department of Orthopedics, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang</aff><aff id="aff3"><label>c</label>Department of Study Center, the First Affiliated Hospital of Harbin Medical University, Harbin, China.</aff><author-notes id="cor1"><corresp><label>∗</label>Correspondence: Qinggang Meng, Department of Plastic Surgery, First Hospital of Harbin, Harbin Medical University, No.151 Diduan Street, Daoli District, Harbin, Heilongjiang Province 150010, China (e-mail: <email>qinggang2000@hotmail.com</email>).</corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>21</day><month>7</month><year>2017</year></pub-date><volume>96</volume><issue>29</issue><elocation-id>e7582</elocation-id><history><date date-type="received"><day>2</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>27</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="medi-96-e7582.pdf"></self-uri><abstract><title><offsets xml_i="4526" xml_f="4534" txt_i="11" txt_f="19">Abstract</offsets></title><sec sec-type="background"><title><offsets xml_i="4576" xml_f="4587" txt_i="20" txt_f="31">Background:</offsets></title><p><offsets xml_i="4598" xml_f="4888" txt_i="32" txt_f="322">Pressure ulcers often seriously affect the quality of life of patients. Moist Exposed Burn Ointment (MEBO) has been developed to treat patients with pressure ulcers. The present study aimed to evaluate the efficacy and safety of MEBO in the treatment of pressure ulcers in Chinese patients.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4929" xml_f="4937" txt_i="324" txt_f="332">Methods:</offsets></title><p><offsets xml_i="4948" xml_f="5291" txt_i="333" txt_f="676">Seventy-two patients with pressure ulcers were randomly assigned to 2 groups who received a placebo or MEBO for 2 months. The primary outcomes included the wound surface area (WSA) and pressure ulcer scale for healing (PUSH) tool. The secondary outcomes included a visual analog scale (VAS), questionnaire of ulcer status, and adverse effects.</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="5332" xml_f="5340" txt_i="678" txt_f="686">Results:</offsets></title><p><offsets xml_i="5351" xml_f="5701" txt_i="687" txt_f="1037">Sixty-seven patients completed the study. After 2 months of treatment, the difference of mean change from the baseline was greater for MEBO (vs placebo) for WSA mean (SD) −6.0 (−8.8, −3.3), PUSH Tool −2.6 (−4.7, −1.5), and VAS score −2.9 (−4.4, −1.7). On the basis of the questionnaire, the pressure ulcers were “completely healed” (50.0% vs 16.7%) (</offsets><italic><offsets xml_i="5709" xml_f="5710" txt_i="1037" txt_f="1038">P</offsets></italic><offsets xml_i="5719" xml_f="5848" txt_i="1038" txt_f="1164"> &lt; .05) in patients after 2 months of treatment with MEBO versus placebo. No major adverse effects were found in the 2 groups.</offsets></p></sec><sec sec-type="conclusion"><title><offsets xml_i="5892" xml_f="5903" txt_i="1166" txt_f="1177">Conclusion:</offsets></title><p><offsets xml_i="5914" xml_f="6035" txt_i="1178" txt_f="1299">We showed that MEBO is effective and well tolerated for improving wound healing in Chinese patients with pressure ulcers.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>clinical trial</kwd><kwd>Moist Exposed Burn Ointment</kwd><kwd>pressure ulcers</kwd><kwd>randomized controlled trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><label><offsets xml_i="6399" xml_f="6400" txt_i="1308" txt_f="1309">1</offsets></label><title><offsets xml_i="6415" xml_f="6427" txt_i="1309" txt_f="1321">Introduction</offsets></title><p><offsets xml_i="6438" xml_f="6504" txt_i="1322" txt_f="1388">Pressure ulcers are very common conditions for bed bound patients.</offsets><sup><offsets xml_i="6509" xml_f="6510" txt_i="1388" txt_f="1389">[</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="6541" xml_f="6542" txt_i="1389" txt_f="1390">1</offsets></xref><offsets xml_i="6549" xml_f="6550" txt_i="1390" txt_f="1391">–</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="6581" xml_f="6582" txt_i="1391" txt_f="1392">7</offsets></xref><offsets xml_i="6589" xml_f="6590" txt_i="1392" txt_f="1393">]</offsets></sup><offsets xml_i="6596" xml_f="6769" txt_i="1393" txt_f="1566"> They are often caused by many factors, such as prolonged pressure on skin. These kinds of ulcers usually occur at bony of the body, such as heals, ankles, hips, and elbows.</offsets><sup><offsets xml_i="6774" xml_f="6775" txt_i="1566" txt_f="1567">[</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="6806" xml_f="6807" txt_i="1567" txt_f="1568">8</offsets></xref><offsets xml_i="6814" xml_f="6815" txt_i="1568" txt_f="1569">,</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="6846" xml_f="6847" txt_i="1569" txt_f="1570">9</offsets></xref><offsets xml_i="6854" xml_f="6855" txt_i="1570" txt_f="1571">]</offsets></sup><offsets xml_i="6861" xml_f="7019" txt_i="1571" txt_f="1729"> If they are not treated adequately, these conditions can seriously affect the quality of life of the patients resulting from pain, disability, and infection.</offsets><sup><offsets xml_i="7024" xml_f="7025" txt_i="1729" txt_f="1730">[</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="7057" xml_f="7059" txt_i="1730" txt_f="1732">10</offsets></xref><offsets xml_i="7066" xml_f="7067" txt_i="1732" txt_f="1733">,</offsets><xref rid="R11" ref-type="bibr"><offsets xml_i="7099" xml_f="7101" txt_i="1733" txt_f="1735">11</offsets></xref><offsets xml_i="7108" xml_f="7109" txt_i="1735" txt_f="1736">]</offsets></sup><offsets xml_i="7115" xml_f="7214" txt_i="1736" txt_f="1835"> These conditions are usually classified into 4 stages according to the pressure ulcers guidelines.</offsets><sup><offsets xml_i="7219" xml_f="7220" txt_i="1835" txt_f="1836">[</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="7252" xml_f="7254" txt_i="1836" txt_f="1838">12</offsets></xref><offsets xml_i="7261" xml_f="7262" txt_i="1838" txt_f="1839">]</offsets></sup></p><p><offsets xml_i="7275" xml_f="7361" txt_i="1840" txt_f="1926">It has been reported that the prevalence of pressure ulcers ranged from 8.8% to 53.2%,</offsets><sup><offsets xml_i="7366" xml_f="7367" txt_i="1926" txt_f="1927">[</offsets><xref rid="R13" ref-type="bibr"><offsets xml_i="7399" xml_f="7401" txt_i="1927" txt_f="1929">13</offsets></xref><offsets xml_i="7408" xml_f="7409" txt_i="1929" txt_f="1930">,</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="7441" xml_f="7443" txt_i="1930" txt_f="1932">14</offsets></xref><offsets xml_i="7450" xml_f="7451" txt_i="1932" txt_f="1933">]</offsets></sup><offsets xml_i="7457" xml_f="7519" txt_i="1933" txt_f="1995"> and the incidence of pressure ulcers varied from 7% to 71.6%.</offsets><sup><offsets xml_i="7524" xml_f="7525" txt_i="1995" txt_f="1996">[</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="7557" xml_f="7559" txt_i="1996" txt_f="1998">15</offsets></xref><offsets xml_i="7566" xml_f="7567" txt_i="1998" txt_f="1999">,</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="7599" xml_f="7601" txt_i="1999" txt_f="2001">16</offsets></xref><offsets xml_i="7608" xml_f="7609" txt_i="2001" txt_f="2002">]</offsets></sup><offsets xml_i="7615" xml_f="7893" txt_i="2002" txt_f="2280"> The annual treatment cost of pressure ulcers is large, for example, in the UK, the cost ranges from 1.4 to 2.1 billion British Pound. It is the same in amount of the total UK National Health Service expenditure on mental illness, or the total cost of community health services.</offsets><sup><offsets xml_i="7898" xml_f="7899" txt_i="2280" txt_f="2281">[</offsets><xref rid="R17" ref-type="bibr"><offsets xml_i="7931" xml_f="7933" txt_i="2281" txt_f="2283">17</offsets></xref><offsets xml_i="7940" xml_f="7941" txt_i="2283" txt_f="2284">]</offsets></sup><offsets xml_i="7947" xml_f="8046" txt_i="2284" txt_f="2383"> Thus, adequate and effective treatment is a very important issue for both patients and clinicians.</offsets></p><p><offsets xml_i="8053" xml_f="8266" txt_i="2384" txt_f="2597">Traditional Chinese medicines, such as herbal medicinal ointments, especially Moist Exposed Burn Ointment (MEBO), and those for acupuncture and moxibustion have been administered to treat pressure ulcers in China.</offsets><sup><offsets xml_i="8271" xml_f="8272" txt_i="2597" txt_f="2598">[</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="8303" xml_f="8304" txt_i="2598" txt_f="2599">1</offsets></xref><offsets xml_i="8311" xml_f="8312" txt_i="2599" txt_f="2600">,</offsets><xref rid="R18" ref-type="bibr"><offsets xml_i="8344" xml_f="8346" txt_i="2600" txt_f="2602">18</offsets></xref><offsets xml_i="8353" xml_f="8354" txt_i="2602" txt_f="2603">–</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="8386" xml_f="8388" txt_i="2603" txt_f="2605">20</offsets></xref><offsets xml_i="8395" xml_f="8396" txt_i="2605" txt_f="2606">]</offsets></sup><offsets xml_i="8402" xml_f="8486" txt_i="2606" txt_f="2690"> In previous studies, MEBO was effectively used to treat burns in clinical practice.</offsets><sup><offsets xml_i="8491" xml_f="8492" txt_i="2690" txt_f="2691">[</offsets><xref rid="R21" ref-type="bibr"><offsets xml_i="8524" xml_f="8526" txt_i="2691" txt_f="2693">21</offsets></xref><offsets xml_i="8533" xml_f="8534" txt_i="2693" txt_f="2694">,</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="8566" xml_f="8568" txt_i="2694" txt_f="2696">22</offsets></xref><offsets xml_i="8575" xml_f="8576" txt_i="2696" txt_f="2697">]</offsets></sup><offsets xml_i="8582" xml_f="8678" txt_i="2697" txt_f="2793"> It consists of sesame oil, β-sitosterol, berberine, and other Chinese herbal plant ingredients.</offsets><sup><offsets xml_i="8683" xml_f="8684" txt_i="2793" txt_f="2794">[</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="8716" xml_f="8718" txt_i="2794" txt_f="2796">23</offsets></xref><offsets xml_i="8725" xml_f="8726" txt_i="2796" txt_f="2797">]</offsets></sup><offsets xml_i="8732" xml_f="8917" txt_i="2797" txt_f="2982"> Further clinical and experimental studies have found that MEBO can not only have analgesic and antimicrobial effects but also can shorten the healing time for patients with burn wound.</offsets><sup><offsets xml_i="8922" xml_f="8923" txt_i="2982" txt_f="2983">[</offsets><xref rid="R21" ref-type="bibr"><offsets xml_i="8955" xml_f="8957" txt_i="2983" txt_f="2985">21</offsets></xref><offsets xml_i="8964" xml_f="8965" txt_i="2985" txt_f="2986">–</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="8997" xml_f="8999" txt_i="2986" txt_f="2988">33</offsets></xref><offsets xml_i="9006" xml_f="9007" txt_i="2988" txt_f="2989">]</offsets></sup><offsets xml_i="9013" xml_f="9151" txt_i="2989" txt_f="3127"> In addition, it can also either induce debridement and epithelial repair, or can save costs of treatment for patients and their families.</offsets><sup><offsets xml_i="9156" xml_f="9157" txt_i="3127" txt_f="3128">[</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="9189" xml_f="9191" txt_i="3128" txt_f="3130">22</offsets></xref><offsets xml_i="9198" xml_f="9199" txt_i="3130" txt_f="3131">,</offsets><xref rid="R25" ref-type="bibr"><offsets xml_i="9231" xml_f="9233" txt_i="3131" txt_f="3133">25</offsets></xref><offsets xml_i="9240" xml_f="9241" txt_i="3133" txt_f="3134">]</offsets></sup><offsets xml_i="9247" xml_f="9368" txt_i="3134" txt_f="3255"> Furthermore, it also has been reported that MEBO can promote the healing for the chronic ischemic and neurogenic ulcers.</offsets><sup><offsets xml_i="9373" xml_f="9374" txt_i="3255" txt_f="3256">[</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="9406" xml_f="9408" txt_i="3256" txt_f="3258">26</offsets></xref><offsets xml_i="9415" xml_f="9416" txt_i="3258" txt_f="3259">,</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="9448" xml_f="9450" txt_i="3259" txt_f="3261">27</offsets></xref><offsets xml_i="9457" xml_f="9458" txt_i="3261" txt_f="3262">]</offsets></sup><offsets xml_i="9464" xml_f="9693" txt_i="3262" txt_f="3491"> However, there is currently limited evidence to evaluate the efficacy and safety of MEBO for treating pressure ulcers. Thus, in the present study, we assessed the efficacy and safety of MEBO for the treatment of pressure ulcers.</offsets></p></sec><sec><label><offsets xml_i="9715" xml_f="9716" txt_i="3493" txt_f="3494">2</offsets></label><title><offsets xml_i="9731" xml_f="9749" txt_i="3494" txt_f="3512">Methods and design</offsets></title><sec><label><offsets xml_i="9769" xml_f="9772" txt_i="3513" txt_f="3516">2.1</offsets></label><title><offsets xml_i="9787" xml_f="9796" txt_i="3516" txt_f="3525">Objective</offsets></title><p><offsets xml_i="9807" xml_f="9925" txt_i="3526" txt_f="3644">The present study aimed to assess the efficacy and adverse effects of MEBO for treating patients with pressure ulcers.</offsets></p></sec><sec><label><offsets xml_i="9947" xml_f="9950" txt_i="3646" txt_f="3649">2.2</offsets></label><title><offsets xml_i="9965" xml_f="9977" txt_i="3649" txt_f="3661">Study design</offsets></title><p><offsets xml_i="9988" xml_f="10722" txt_i="3662" txt_f="4396">This study is a multicenter randomized controlled clinical trial with 2 parallel arms. The trial was conducted at the First Hospital of Harbin and Hongqi Hospital of Mudanjiang Medical College between January 1, 2014, and May 30, 2015. It was approved by the ethics review boards of the First Hospital of Harbin and Hongqi Hospital of Mudanjiang Medical College, respectively. Written informed consent was obtained from all patients before enrollment. Eligible patients were randomized in a ratio of 1:1 to the MEBO and placebo groups, and received treatment for 2 months. Outcome measures were assessed at the baseline, 1, and 2 months after randomization. Results data were analyzed by professionals blinded to the group allocation.</offsets></p></sec><sec><label><offsets xml_i="10744" xml_f="10747" txt_i="4398" txt_f="4401">2.3</offsets></label><title><offsets xml_i="10762" xml_f="10773" txt_i="4401" txt_f="4412">Eligibility</offsets></title><sec><label><offsets xml_i="10793" xml_f="10798" txt_i="4413" txt_f="4418">2.3.1</offsets></label><title><offsets xml_i="10813" xml_f="10831" txt_i="4418" txt_f="4436">Inclusion criteria</offsets></title><p><offsets xml_i="10842" xml_f="11079" txt_i="4437" txt_f="4674">Participants were included if they met the following criteria: aged 18 to 75 years; pressure ulcers were at stage III or IV according to the european pressure ulcer advisory panel/national pressure ulcer advisory panel (NPUAP) guidelines</offsets><sup><offsets xml_i="11084" xml_f="11085" txt_i="4674" txt_f="4675">[</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="11117" xml_f="11119" txt_i="4675" txt_f="4677">12</offsets></xref><offsets xml_i="11126" xml_f="11127" txt_i="4677" txt_f="4678">]</offsets></sup><offsets xml_i="11133" xml_f="11165" txt_i="4678" txt_f="4710">; and at least 1 pressure ulcer.</offsets></p></sec><sec><label><offsets xml_i="11187" xml_f="11192" txt_i="4712" txt_f="4717">2.3.2</offsets></label><title><offsets xml_i="11207" xml_f="11225" txt_i="4717" txt_f="4735">Exclusion criteria</offsets></title><p><offsets xml_i="11236" xml_f="11598" txt_i="4736" txt_f="5098">Patients were excluded as follows: undertaking other therapies that could affect healing, such as corticosteroids, radiation therapy, or chemotherapy for cancer; complications of peripheral vascular disease, malignant tumors, diabetes mellitus, or infection; and severe diseases, including liver, cardiac, and kidney diseases, and serious relevant complications.</offsets></p></sec></sec><sec><label><offsets xml_i="11626" xml_f="11629" txt_i="5101" txt_f="5104">2.4</offsets></label><title><offsets xml_i="11644" xml_f="11684" txt_i="5104" txt_f="5144">Randomization and allocation concealment</offsets></title><p><offsets xml_i="11695" xml_f="12106" txt_i="5145" txt_f="5556">Stratified randomization schedule was conducted by a statistician of the First Hospital of Harbin using the software of Statistical Analysis System (SAS) package (Version 9.1.3; SAS Institute Inc., Cary, NC). Seventy-two qualified subjects were allocated to the MEBO group or placebo group equally. The allocation concealment was blinded to the participants, investigators, outcome assessors, and data analysts.</offsets></p></sec><sec><label><offsets xml_i="12128" xml_f="12131" txt_i="5558" txt_f="5561">2.5</offsets></label><title><offsets xml_i="12146" xml_f="12158" txt_i="5561" txt_f="5573">Intervention</offsets></title><p><offsets xml_i="12169" xml_f="13135" txt_i="5574" txt_f="6540">All patients in both groups received position change every 2 hours, and mattress that helped to protect the vulnerable skin. In addition, medications for pain control and infection prevention were also applied. As for pain control, patients were given ibuprofen 200 mg (1 tablet) each time for every 6 hours as needed. As for infection prevention, povidone iodine (Betadine solution; Chengdu Yongan Pharmaceutical Co.,Ltd., Chengdu, China) was used to clean pressure ulcers before MEBO or placebo intervention. Then, the pressure ulcers were cleansed with normal saline gauze. MEBO was smeared successively onto the wounds at a thickness of 1 mm twice daily with a sterile gloved finger. The MEBO was not removed in the first 4 days of the treatment. On the fifth day, the accumulated MEBO was removed with a finely serrated metal spatula. Then, MEBO was freshly applied twice daily. The total treatment lasted 2 months. The same application was used as for placebo.</offsets></p></sec><sec><label><offsets xml_i="13157" xml_f="13160" txt_i="6542" txt_f="6545">2.6</offsets></label><title><offsets xml_i="13175" xml_f="13191" txt_i="6545" txt_f="6561">Outcome measures</offsets></title><sec><label><offsets xml_i="13211" xml_f="13216" txt_i="6562" txt_f="6567">2.6.1</offsets></label><title><offsets xml_i="13231" xml_f="13247" txt_i="6567" txt_f="6583">Primary outcomes</offsets></title><p><offsets xml_i="13258" xml_f="13389" txt_i="6584" txt_f="6715">The primary outcomes were evaluated by the wound surface area (WSA) and pressure ulcer scale for healing (PUSH) tool. The PUSH tool</offsets><sup><offsets xml_i="13394" xml_f="13395" txt_i="6715" txt_f="6716">[</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="13427" xml_f="13429" txt_i="6716" txt_f="6718">28</offsets></xref><offsets xml_i="13436" xml_f="13437" txt_i="6718" txt_f="6719">]</offsets></sup><offsets xml_i="13443" xml_f="13867" txt_i="6719" txt_f="7143"> was developed by NPUAP as a quick, reliable tool to monitor the change in pressure ulcer status. It categorized ulcers with respect to surface area, exudate, and type of wound tissue. In addition, if a patient had more than 1 ulcer, all the ulcers were treated by the same method to eliminate the possible complicating factor of treatment interactions. However, only the largest WSA was measured and analyzed in this study.</offsets></p></sec><sec><label><offsets xml_i="13889" xml_f="13894" txt_i="7145" txt_f="7150">2.6.2</offsets></label><title><offsets xml_i="13909" xml_f="13927" txt_i="7150" txt_f="7168">Secondary outcomes</offsets></title><p><offsets xml_i="13938" xml_f="14178" txt_i="7169" txt_f="7409">The secondary outcome was assessed using the visual analog scale (VAS) and a questionnaire of ulcer status. The pain intensity of pressure ulcers was assessed using the 10-point VAS scale (0, absence of pain; 10, the worst pain imaginable).</offsets><sup><offsets xml_i="14183" xml_f="14184" txt_i="7409" txt_f="7410">[</offsets><xref rid="R29" ref-type="bibr"><offsets xml_i="14216" xml_f="14218" txt_i="7410" txt_f="7412">29</offsets></xref><offsets xml_i="14225" xml_f="14226" txt_i="7412" txt_f="7413">,</offsets><xref rid="R30" ref-type="bibr"><offsets xml_i="14258" xml_f="14260" txt_i="7413" txt_f="7415">30</offsets></xref><offsets xml_i="14267" xml_f="14268" txt_i="7415" txt_f="7416">]</offsets></sup><offsets xml_i="14274" xml_f="15117" txt_i="7416" txt_f="8259"> A questionnaire regarding the ulcer status was completed by the practitioners. At the end of 2 months, the ulcers were examined blindly and assessed as “Completely Healed,” “Partially Healed,” “Without Improvement,” or “Worsening.” The WSA was traced by a paper overlay around the ulcer borders, and measured using AutoCAD 2000 software (AutoCAD, CA). “Completely healed” was defined as an intact dermis and epidermis, and no abrasion or ulceration. “Partially healed” was defined as any decrease in ulcer size compared with the baseline ulcer tracing, but excluding complete healing. “Without improvement was defined as no change in ulcer size compared with the baseline ulcer tracing. Worsening” was defined as any increase in ulcer size compared with the baseline ulcer tracing. In addition, adverse effects were recorded to assess safety.</offsets></p></sec></sec><sec><label><offsets xml_i="15145" xml_f="15148" txt_i="8262" txt_f="8265">2.7</offsets></label><title><offsets xml_i="15163" xml_f="15183" txt_i="8265" txt_f="8285">Statistical analyses</offsets></title><p><offsets xml_i="15194" xml_f="15414" txt_i="8286" txt_f="8506">Data were analyzed by a statistician blinded to the group allocations using the Statistical Package for the Social Sciences (SPSS) 15.0 statistical software package (SPSS Inc., Chicago, IL). Significance was reported at </offsets><italic><offsets xml_i="15422" xml_f="15423" txt_i="8506" txt_f="8507">P</offsets></italic><offsets xml_i="15432" xml_f="15600" txt_i="8507" txt_f="8672"> &lt; .05. Data analysis of the baseline characteristics of primary and secondary outcomes was based on the intention-to-treat (ITT) principle. We used the Chi-square, </offsets><italic><offsets xml_i="15608" xml_f="15609" txt_i="8672" txt_f="8673">t</offsets></italic><offsets xml_i="15618" xml_f="15830" txt_i="8673" txt_f="8885">, and Fisher exact tests to analyze the outcome data. The required sample size of this study was estimated to be 72 subjects, 36 in each group with α = 0.5, β = 0.8. It assumed that there was a 20% drop-out rate.</offsets></p></sec></sec><sec><label><offsets xml_i="15858" xml_f="15859" txt_i="8888" txt_f="8889">3</offsets></label><title><offsets xml_i="15874" xml_f="15881" txt_i="8889" txt_f="8896">Results</offsets></title><p><offsets xml_i="15892" xml_f="15970" txt_i="8897" txt_f="8975">One hundred thirty-five patients were initially recruited in this study (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="16000" xml_f="16001" txt_i="8975" txt_f="8976">1</offsets></xref><offsets xml_i="16008" xml_f="16396" txt_i="8976" txt_f="9364">). Of these 135 participants, 51 individuals did not meet the inclusion criteria, and 12 refused to involve the present study. Therefore, 72 patients were included and then randomly divided into 2 groups in this study. All outcome data in this study were analyzed by ITT approach. Five patients withdrew from the present study because of their medicine change and lost to follow-up (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="16426" xml_f="16427" txt_i="9364" txt_f="9365">1</offsets></xref><offsets xml_i="16434" xml_f="16436" txt_i="9365" txt_f="9367">).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="16477" xml_f="16485" txt_i="9368" txt_f="9376">Figure 1</offsets></label><caption><p><offsets xml_i="16505" xml_f="16544" txt_i="9376" txt_f="9415">Flow of participants through the trial.</offsets></p></caption><graphic xlink:href="medi-96-e7582-g001"></graphic></fig><p><offsets xml_i="16618" xml_f="16703" txt_i="9416" txt_f="9501">Characteristics of all included participants at the baseline are summarized in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="16735" xml_f="16736" txt_i="9501" txt_f="9502">1</offsets></xref><offsets xml_i="16743" xml_f="17090" txt_i="9502" txt_f="9849">. The 2 groups did not differ significantly at baseline. At the baseline, the mean age (SD) was 71.5 (20.4) years in the MEBO group and 69.8 (21.4) years in the placebo group. All patients in each group were Chinese. The duration of the pressure ulcers was 5.1 (1.9) and 5.0 (1.7) months in the MEBO and placebo groups, respectively. The BMI (kg/m</offsets><sup><offsets xml_i="17095" xml_f="17096" txt_i="9849" txt_f="9850">2</offsets></sup><offsets xml_i="17102" xml_f="17544" txt_i="9850" txt_f="10292">) was 24.4 (6.1) for males and 20.9 (4.2) for females in the MEBO group, and 23.9 (5.7) for males and 20.7 (4.1) for females in the placebo group. The length of hospital stay was 4.5 (1.3) months in the MEBO group and 4.3 (1.7) months in the placebo group. The stages of pressure ulcers were IV [12 (33.3%) in the MEBO group and 16 (44.4%) in the placebo group] and III [24 (66.7%) vs 20 (55.6%) in the MEBO and placebo groups, respectively].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="17592" xml_f="17599" txt_i="10293" txt_f="10300">Table 1</offsets></label><caption><p><offsets xml_i="17619" xml_f="17663" txt_i="10300" txt_f="10344">Characteristics of participants at baseline.</offsets></p></caption><graphic xlink:href="medi-96-e7582-g002"></graphic></table-wrap><p><offsets xml_i="17744" xml_f="18133" txt_i="10345" txt_f="10734">At the baseline, the mean WSA (SD), PUSH tool, and VAS were 18.4 (13.5), 11.9 (1.5), 5.9 (1.2) in the MEBO group, respectively, and 17.9 (12.8), 11.7 (1.5), 6.1 (1.4) in the placebo group, respectively. After 1 month of treatment, the difference of adjusted mean change from the baseline was −4.9 (−6.9, −3.4), −1.8 (−2.5, −1.3), and −1.4 (−1.9, −0.9), respectively, between the 2 groups (</offsets><italic><offsets xml_i="18141" xml_f="18142" txt_i="10734" txt_f="10735">P</offsets></italic><offsets xml_i="18151" xml_f="18152" txt_i="10735" txt_f="10736"> </offsets><italic><offsets xml_i="18160" xml_f="18164" txt_i="10736" txt_f="10737">&lt;</offsets></italic><offsets xml_i="18173" xml_f="18185" txt_i="10737" txt_f="10749"> .01; Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="18217" xml_f="18218" txt_i="10749" txt_f="10750">2</offsets></xref><offsets xml_i="18225" xml_f="18373" txt_i="10750" txt_f="10898">). After 2 months of treatment, these changes were −6.0 (−8.8, −3.3), −2.6 (−4.7, −1.5), and −2.9 (−4.4, −1.7), respectively, between the 2 groups (</offsets><italic><offsets xml_i="18381" xml_f="18382" txt_i="10898" txt_f="10899">P</offsets></italic><offsets xml_i="18391" xml_f="18392" txt_i="10899" txt_f="10900"> </offsets><italic><offsets xml_i="18400" xml_f="18404" txt_i="10900" txt_f="10901">&lt;</offsets></italic><offsets xml_i="18413" xml_f="18425" txt_i="10901" txt_f="10913"> .01; Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="18457" xml_f="18458" txt_i="10913" txt_f="10914">2</offsets></xref><offsets xml_i="18465" xml_f="18467" txt_i="10914" txt_f="10916">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="18515" xml_f="18522" txt_i="10917" txt_f="10924">Table 2</offsets></label><caption><p><offsets xml_i="18542" xml_f="18630" txt_i="10924" txt_f="11012">Primary and secondary outcomes at 1 and 2 months after treatment (change from baseline).</offsets></p></caption><graphic xlink:href="medi-96-e7582-g003"></graphic></table-wrap><p><offsets xml_i="18711" xml_f="18902" txt_i="11013" txt_f="11204">Analysis of the healing status of pressure ulcers after 2 months found that ulcers in 50.0% of patients in the MEBO group and 16.7% of those in the placebo group underwent completely healed (</offsets><italic><offsets xml_i="18910" xml_f="18911" txt_i="11204" txt_f="11205">P</offsets></italic><offsets xml_i="18920" xml_f="18921" txt_i="11205" txt_f="11206"> </offsets><italic><offsets xml_i="18929" xml_f="18933" txt_i="11206" txt_f="11207">&lt;</offsets></italic><offsets xml_i="18942" xml_f="18954" txt_i="11207" txt_f="11219"> .05; Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="18986" xml_f="18987" txt_i="11219" txt_f="11220">3</offsets></xref><offsets xml_i="18994" xml_f="19073" txt_i="11220" txt_f="11299">). In addition, no patients in the 2 groups reported any major adverse effects.</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="19121" xml_f="19128" txt_i="11300" txt_f="11307">Table 3</offsets></label><caption><p><offsets xml_i="19148" xml_f="19219" txt_i="11307" txt_f="11378">Healing status of pressure ulcers after 2 months treatment in 2 groups.</offsets></p></caption><graphic xlink:href="medi-96-e7582-g004"></graphic></table-wrap></sec><sec><label><offsets xml_i="19315" xml_f="19316" txt_i="11380" txt_f="11381">4</offsets></label><title><offsets xml_i="19331" xml_f="19341" txt_i="11381" txt_f="11391">Discussion</offsets></title><p><offsets xml_i="19352" xml_f="19520" txt_i="11392" txt_f="11560">Pressure ulcers are widespread chronic wounds. They often inflict extensive damage to the skin, and the recovery time often exceeds 3 months, because of the chronicity.</offsets><sup><offsets xml_i="19525" xml_f="19526" txt_i="11560" txt_f="11561">[</offsets><xref rid="R31" ref-type="bibr"><offsets xml_i="19558" xml_f="19560" txt_i="11561" txt_f="11563">31</offsets></xref><offsets xml_i="19567" xml_f="19568" txt_i="11563" txt_f="11564">]</offsets></sup><offsets xml_i="19574" xml_f="19814" txt_i="11564" txt_f="11804"> The incidence of pressure ulcers will possibly grow rapidly in the future due to increased life expectancy and aging. However, although various methods are used to treat pressure ulcers, no standard therapy has previously been established.</offsets></p><p><offsets xml_i="19821" xml_f="20048" txt_i="11805" txt_f="12032">MEBO has been widely used in China for treating wounds, especially for burn healing. Several clinical trials were conducted to evaluate the efficacy of MEBO, and determined that MEBO had a positive effect on burn wound healing.</offsets><sup><offsets xml_i="20053" xml_f="20054" txt_i="12032" txt_f="12033">[</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="20086" xml_f="20088" txt_i="12033" txt_f="12035">22</offsets></xref><offsets xml_i="20095" xml_f="20096" txt_i="12035" txt_f="12036">,</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="20128" xml_f="20130" txt_i="12036" txt_f="12038">24</offsets></xref><offsets xml_i="20137" xml_f="20138" txt_i="12038" txt_f="12039">,</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="20170" xml_f="20172" txt_i="12039" txt_f="12041">26</offsets></xref><offsets xml_i="20179" xml_f="20180" txt_i="12041" txt_f="12042">,</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="20212" xml_f="20214" txt_i="12042" txt_f="12044">27</offsets></xref><offsets xml_i="20221" xml_f="20222" txt_i="12044" txt_f="12045">,</offsets><xref rid="R32" ref-type="bibr"><offsets xml_i="20254" xml_f="20256" txt_i="12045" txt_f="12047">32</offsets></xref><offsets xml_i="20263" xml_f="20264" txt_i="12047" txt_f="12048">]</offsets></sup><offsets xml_i="20270" xml_f="20404" txt_i="12048" txt_f="12182"> The possible mechanisms of MEBO for treating wounds are that it provides a moist environment for the wound healing of pressure ulcers</offsets><sup><offsets xml_i="20409" xml_f="20410" txt_i="12182" txt_f="12183">[</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="20442" xml_f="20444" txt_i="12183" txt_f="12185">33</offsets></xref><offsets xml_i="20451" xml_f="20452" txt_i="12185" txt_f="12186">]</offsets></sup><offsets xml_i="20458" xml_f="20508" txt_i="12186" txt_f="12236"> and exhibits analgesic and antimicrobial effects.</offsets><sup><offsets xml_i="20513" xml_f="20514" txt_i="12236" txt_f="12237">[</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="20546" xml_f="20548" txt_i="12237" txt_f="12239">22</offsets></xref><offsets xml_i="20555" xml_f="20556" txt_i="12239" txt_f="12240">]</offsets></sup><offsets xml_i="20562" xml_f="20688" txt_i="12240" txt_f="12366"> In addition, MEBO can increase neovascularization in granulation tissue, and enhance vascular endothelial cell proliferation.</offsets><sup><offsets xml_i="20693" xml_f="20694" txt_i="12366" txt_f="12367">[</offsets><xref rid="R34" ref-type="bibr"><offsets xml_i="20726" xml_f="20728" txt_i="12367" txt_f="12369">34</offsets></xref><offsets xml_i="20735" xml_f="20736" txt_i="12369" txt_f="12370">]</offsets></sup><offsets xml_i="20742" xml_f="20888" txt_i="12370" txt_f="12516"> It can also increase fibroblast cells in the granulation tissue and help them migrate from the surrounding connective tissue into the wound site.</offsets><sup><offsets xml_i="20893" xml_f="20894" txt_i="12516" txt_f="12517">[</offsets><xref rid="R35" ref-type="bibr"><offsets xml_i="20926" xml_f="20928" txt_i="12517" txt_f="12519">35</offsets></xref><offsets xml_i="20935" xml_f="20936" txt_i="12519" txt_f="12520">]</offsets></sup></p><p><offsets xml_i="20949" xml_f="21322" txt_i="12521" txt_f="12894">To the best of our knowledge, the present study is the first multicenter randomized controlled trial to evaluate the efficacy and safety of MEBO for treating pressure ulcers in China. It was designed strictly with assessor and analyst blinding. The results demonstrated that MEBO was an effective therapy for improving pressure ulcer healing when compared with the placebo.</offsets></p><p><offsets xml_i="21329" xml_f="21774" txt_i="12895" txt_f="13340">However, the present study has some limitations. First, all patients kept their daily medication treatment, because it was impossible to stop the medication intervention for patients with pressure ulcers. Thus, the achieved effectiveness may have been affected by the additional effects of the medication. Second, this study did not have a follow-up evaluation. Therefore, the efficacy of longer term after treatment is needed in future studies.</offsets></p></sec><sec><label><offsets xml_i="21796" xml_f="21797" txt_i="13342" txt_f="13343">5</offsets></label><title><offsets xml_i="21812" xml_f="21822" txt_i="13343" txt_f="13353">Conclusion</offsets></title><p><offsets xml_i="21833" xml_f="22087" txt_i="13354" txt_f="13608">The results of the present study provide evidence to support the hypothesis that MEBO is an effective and safe therapy for treating pressure ulcers in Chinese patients. However, larger studies conducted over a longer treatment period are still warranted.</offsets></p></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: GCP = good clinical practice, ITT = intention-to-treat, MEBO = Moist Exposed Burn Ointment, PUSH = pressure ulcer scale for healing tool, SAS = Statistical Analysis System package, SPSS = Statistical Package for the Social Sciences, VAS = visual analog scale, WSA = wound surface area.</p></fn><fn fn-type="equal"><p>WL and YM contributed to this study equally.</p></fn><fn fn-type="supported-by"><p>Funding/support: This study was funded by grants from the Health Department of Heilongjiang province (2012-690,2009-174), the Project of Science and Technology Program of Heilongjiang province (GC10C303-4), the Science and Technology Talents Program of Harbin (2012RFXXS066, 2014RFXGJ041, 2014RFQGJ094, 2014RFXGJ035), and the Department of Education Project of Heilongjiang province (11541147), Post Doctoral Fund (160780); Heilongjiang Natural Science Foundation (QC2016102, H2016002).</p></fn><fn fn-type="COI-statement"><p>The authors report no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QH</given-names></name><name><surname>Sun</surname><given-names>ZR</given-names></name><name><surname>Yue</surname><given-names>JH</given-names></name><etal></etal></person-group>
<article-title>Traditional Chinese medicine for pressure ulcer: a meta-analysis</article-title>. <source>Int Wound J</source>
<year>2013</year>;<volume>10</volume>:<fpage>221</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">22512889</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitney</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>L</given-names></name><name><surname>Aslam</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Guidelines for the treatment of pressure ulcers</article-title>. <source>Wound Repair Regen</source>
<year>2006</year>;<volume>14</volume>:<fpage>663</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">17199832</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>M</given-names></name><name><surname>Gill</surname><given-names>SS</given-names></name><name><surname>Kalkar</surname><given-names>SR</given-names></name><etal></etal></person-group>
<article-title>Treatment of pressure ulcers: a systematic review</article-title>. <source>JAMA</source>
<year>2008</year>;<volume>300</volume>:<fpage>2647</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">19066385</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Yue</surname><given-names>J</given-names></name></person-group>
<article-title>Massage therapy for preventing pressure ulcers</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2015</year>
<fpage>CD010518</fpage>.<pub-id pub-id-type="pmid">26081072</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Yue</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group>
<article-title>Local warming therapy for treating chronic wounds</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2015</year>
<fpage>CD011728</fpage>.</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeidinia</surname><given-names>A</given-names></name><name><surname>Keihanian</surname><given-names>F</given-names></name><name><surname>Lashkari</surname><given-names>AP</given-names></name><etal></etal></person-group>
<article-title>Partial-thickness burn wounds healing by topical treatment: a randomized controlled comparison between silver sulfadiazine and centiderm</article-title>. <source>Medicine (Baltimore)</source>
<year>2017</year>;<volume>96</volume>:<fpage>e6168</fpage>.<pub-id pub-id-type="pmid">28248871</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Krug</surname><given-names>K</given-names></name><name><surname>Brogan</surname><given-names>MS</given-names></name></person-group>
<article-title>Physical therapy in wound care: a cost-effectiveness analysis</article-title>. <source>Medicine (Baltimore)</source>
<year>2015</year>;<volume>94</volume>:<fpage>e2202</fpage>.<pub-id pub-id-type="pmid">26656352</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torpy</surname><given-names>JM</given-names></name><name><surname>Lynm</surname><given-names>C</given-names></name><name><surname>Glass</surname><given-names>RM</given-names></name></person-group>
<article-title>Pressure ulcers</article-title>. <source>JAMA</source>
<year>2003</year>;<volume>289</volume>:<fpage>254</fpage>.<pub-id pub-id-type="pmid">12517212</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeller</surname><given-names>JL</given-names></name><name><surname>Lynm</surname><given-names>C</given-names></name><name><surname>Glass</surname><given-names>RM</given-names></name></person-group>
<article-title>Pressure ulcers</article-title>. <source>JAMA</source>
<year>2006</year>;<volume>296</volume>:<fpage>1020</fpage>.<pub-id pub-id-type="pmid">16926361</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Teng</surname><given-names>M</given-names></name></person-group>
<article-title>Effectiveness of autologous stem cell therapy for the treatment of lower extremity ulcers: a systematic review and meta-analysis</article-title>. <source>Medicine (Baltimore)</source>
<year>2016</year>;<volume>95</volume>:<fpage>e2716</fpage>.<pub-id pub-id-type="pmid">26986097</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Shen</surname><given-names>JH</given-names></name><etal></etal></person-group>
<article-title>Demonstrating a conceptual framework to provide efficient wound management service for a wound care center in a tertiary hospital</article-title>. <source>Medicine (Baltimore)</source>
<year>2015</year>;<volume>94</volume>:<fpage>e1962</fpage>.<pub-id pub-id-type="pmid">26554805</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="book"><collab>European Pressure Advisory Panel, National Pressure Ulcer Advisory Panel</collab>. <article-title>Prevention and Treatment of Pressure Ulcers: Quick Reference Guide</article-title>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Pressure Ulcer Advisory Panel</publisher-name>; <year>2009</year>.</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>CM</given-names></name><name><surname>Caseby</surname><given-names>NG</given-names></name></person-group>
<article-title>Prevalence and incidence studies of pressure ulcers in two long-term care facilities in Canada</article-title>. <source>Ostomy Wound Manage</source>
<year>2001</year>;<volume>47</volume>:<fpage>28</fpage>–<lpage>34</lpage>.</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannen</surname><given-names>A</given-names></name><name><surname>Bours</surname><given-names>G</given-names></name><name><surname>Halfens</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>A comparison of pressure ulcer prevalence rates in nursing homes in the Netherlands and Germany, adjusted for population characteristics</article-title>. <source>Res Nurs Health</source>
<year>2006</year>;<volume>29</volume>:<fpage>588</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">17131273</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JR</given-names></name><name><surname>Gibran</surname><given-names>NS</given-names></name><name><surname>Engrav</surname><given-names>LH</given-names></name><etal></etal></person-group>
<article-title>Incidence and characteristics of hospitalized patients with pressure ulcers: State of Washington, 1987 to 2000</article-title>. <source>Plast Reconstr Surg</source>
<year>2006</year>;<volume>117</volume>:<fpage>630</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">16462349</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittington</surname><given-names>KT</given-names></name><name><surname>Briones</surname><given-names>R</given-names></name></person-group>
<article-title>National prevalence and incidence study: 6-year sequential acute care data</article-title>. <source>Adv Skin Wound Care</source>
<year>2004</year>;<volume>17</volume>:<fpage>490</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">15632743</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>G</given-names></name><name><surname>Dealey</surname><given-names>C</given-names></name><name><surname>Posnett</surname><given-names>J</given-names></name></person-group>
<article-title>The cost of pressure ulcers in the UK</article-title>. <source>Age Ageing</source>
<year>2004</year>;<volume>33</volume>:<fpage>230</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">15082426</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QH</given-names></name><name><surname>Yue</surname><given-names>JH</given-names></name><name><surname>Sun</surname><given-names>ZR</given-names></name></person-group>
<article-title>Electroacupuncture for pressure ulcer: a study protocol for a randomized controlled pilot trial</article-title>. <source>Trials</source>
<year>2014</year>;<volume>15</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">24393344</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QH</given-names></name><name><surname>Yue</surname><given-names>JH</given-names></name><name><surname>Li</surname><given-names>CR</given-names></name><etal></etal></person-group>
<article-title>Moxibustion for the treatment of pressure ulcers: study protocol for a pilot, multicentre, randomised controlled trial</article-title>. <source>Br Med J Open</source>
<year>2014</year>;<volume>4</volume>:<fpage>e006423</fpage>.</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>A case of electroacupuncture therapy for pressure ulcer</article-title>. <source>Acupunct Med</source>
<year>2013</year>;<volume>31</volume>:<fpage>450</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="pmid">23917394</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allam</surname><given-names>AM</given-names></name><name><surname>Mostafa</surname><given-names>W</given-names></name><name><surname>Zayed</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Management of the acute partial-thickness burned hand; moist exposed burn ointment or silver sulphadiazine cream both combined with a polyethylene bag</article-title>. <source>Ann Burns Fire Disasters</source>
<year>2007</year>;<volume>20</volume>:<fpage>144</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">21991086</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>T</given-names></name><name><surname>Ashkar</surname><given-names>W</given-names></name><name><surname>Schumacher</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Moist exposed burn ointment (MEBO) in partial thickness burns: a randomized, comparative open mono-center study on the efficacy of dermaheal (MEBO) ointment on thermal 2nd degree burns compared to conventional therapy</article-title>. <source>Eur J Med Res</source>
<year>2008</year>;<volume>13</volume>:<fpage>505</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">19073386</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>YL</given-names></name></person-group>
<article-title>Analysis of MEBO Cream Institute of Science and Forensic Medicine</article-title>. <year>1999</year>;<publisher-loc>Singapore</publisher-loc>: <publisher-name>Department of Scientific Services, Health Science Division</publisher-name>, <comment>Report no. 99033191</comment>.</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jewo</surname><given-names>PI</given-names></name><name><surname>Fadeyibi</surname><given-names>IO</given-names></name><name><surname>Babalola</surname><given-names>OS</given-names></name><etal></etal></person-group>
<article-title>A comparative study of the wound healing properties of moist exposed burn ointment (MEBO) and silver sulphadiazine</article-title>. <source>Ann Burns Fire Disasters</source>
<year>2009</year>;<volume>22</volume>:<fpage>79</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">21991159</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurjus</surname><given-names>A</given-names></name><name><surname>Atiyeh</surname><given-names>BS</given-names></name><name><surname>Abdallah</surname><given-names>IM</given-names></name><etal></etal></person-group>
<article-title>Pharmacological modulation of wound healing in experimental burns</article-title>. <source>Burns</source>
<year>2007</year>;<volume>33</volume>:<fpage>892</fpage>–<lpage>907</lpage>.<pub-id pub-id-type="pmid">17521821</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>QS</given-names></name><name><surname>Tang</surname><given-names>QL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>MEBO for treating 47 cases of chronic ischemic ulcer in lower limber</article-title>. <source>Chin J Burns Wound Surface Ulcer</source>
<year>2005</year>;<volume>17</volume>:<fpage>296</fpage>–<lpage>7</lpage>. <comment>(In Chinese)</comment>.</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>QL</given-names></name><etal></etal></person-group>
<article-title>Clinical observation on effect of MEBO on neurogenic ulcer</article-title>. <source>Liaoning J Tradit Chin Med</source>
<year>2012</year>;<volume>39</volume>:<fpage>1095</fpage>–<lpage>6</lpage>. <comment>(In Chinese)</comment>.</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="book"><collab>National Pressure Ulcer Advisory Panel (NPUAP)</collab>. <source>PUSH Tool</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Pressure Ulcer Advisory Panel</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revill</surname><given-names>SI</given-names></name><name><surname>Robinson</surname><given-names>JO</given-names></name><name><surname>Rosen</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>The reliability of a linear analogue for evaluating pain</article-title>. <source>Anaesthesia</source>
<year>1976</year>;<volume>31</volume>:<fpage>1191</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">1015603</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>AM</given-names></name></person-group>
<article-title>Assessment of chronic pain. 1. Aspects of the reliability and validity of the visual analogue scale</article-title>. <source>Pain</source>
<year>1983</year>;<volume>16</volume>:<fpage>87</fpage>–<lpage>101</lpage>.<pub-id pub-id-type="pmid">6602967</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>MC</given-names></name><name><surname>Tuma</surname><given-names>P</given-names><suffix>Jr</suffix></name><name><surname>Carvalho</surname><given-names>VF</given-names></name><etal></etal></person-group>
<article-title>Complex wounds</article-title>. <source>Clinics (Sao Paulo)</source>
<year>2006</year>;<volume>61</volume>:<fpage>571</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">17187095</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ang</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Gan</surname><given-names>CS</given-names></name><etal></etal></person-group>
<article-title>Pain control in a randomized, controlled, clinical trial comparing moist exposed burnointment and conventional methods in patients with partial-thickness burns</article-title>. <source>J Burn Care Rehabil</source>
<year>2003</year>;<volume>24</volume>:<fpage>289</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">14501397</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>RX</given-names></name></person-group>
<article-title>The medicine of burns and ulcers, a general introduction</article-title>. <source>Chin J Burns Wounds Surf Ulcers</source>
<year>1989</year>;<volume>1</volume>:<fpage>11</fpage>–<lpage>21</lpage>.</mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>QL</given-names></name><name><surname>Han</surname><given-names>SS</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Moist exposed burn ointment promotes cutaneous excisional wound healing in rats involving VEGF and bFGF</article-title>. <source>Mol Med Rep</source>
<year>2014</year>;<volume>9</volume>:<fpage>1277</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">24469608</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmoulière</surname><given-names>A</given-names></name><name><surname>Chaponnier</surname><given-names>C</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name></person-group>
<article-title>Tissue repair, contraction, and the myofibroblast</article-title>. <source>Wound Repair Regen</source>
<year>2005</year>;<volume>13</volume>:<fpage>7</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">15659031</pub-id></mixed-citation></ref></ref-list></back></article>